GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Financiere de Tubize SA (XBRU:TUB) » Definitions » Valuation Rank

Financiere de Tubize (XBRU:TUB) Valuation Rank


View and export this data going back to 1985. Start your Free Trial

What is Financiere de Tubize Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Financiere de Tubize Valuation Rank Related Terms

Thank you for viewing the detailed overview of Financiere de Tubize's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Financiere de Tubize (XBRU:TUB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Financiere de Tubize SA (XBRU:TUB) » Definitions » Valuation Rank
Comparable Companies
XBRU:HYL XBRU:ONWD XBRU:ALIMG XBRU:CYAD XBRU:BIOS XBRU:OXUR XBRU:ARGX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX OCSE:GMAB ALNY BGNE BMRN
Traded in Other Exchanges
FTD:Germany
Address
Allée de la Recherche, 60, Brussels, BEL, 1070
Website
https://www.financiere-tubize.be
Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a global biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. Most of its sales revenue is derived from its neurology products, followed by its immunology products. The company's strategy focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.